BlackRock Fund Advisors recently announced the acquisition of new stake in Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP). The institutional investor has increased its shareholding in the Healthcare company by 9.97% to 5.09 million shares with purchase of 0.46 million shares. This fresh investment now brings its stake to 7.02% valued currently at $31.91 million. In addition, Carmignac Gestion SA raised its holdings by 3.04 million to 3.77 million shares. And Carmignac Gestion Luxembourg SA (.. has lifted its position by 415.65% or 3.04 million shares – to 3.77 million shares.
With over 2.37 million Corbus Pharmaceuticals Holdings Inc. (CRBP) shares trading Friday and a closing price of $9.12 on the day, the dollar volume was approximately $21.6 million. The shares have shown a positive weekly performance of 15.30% and its price on 08/28/20 gained nearly 6.54%. Currently, there are 73.89M common shares owned by the public and among those 73.07M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 6 analysts who have offered their price forecasts for CRBP have a consensus price objective of $24.83. The analysts have set the share’s price value over the next 12 months at a high of $40.00 and a low of $18.00 should the stock experience a downside. Incidentally, analysts’ outlook for the Corbus Pharmaceuticals Holdings Inc. stock is 1.60 for the next 12 months. But an upside of 77.2% will see the stock hit the forecast high price target while mean target price for the stock is $22.50.
Insiders at the company have transacted a total of 8 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 8 of these insider trades were purchases, accounting for 33,100 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The top 3 mutual fund holders in Corbus Pharmaceuticals Holdings Inc. are ETFMG Alternative Harvest ETF, Carmignac Portfolio – Long-Short, and SPDR S&P Biotech ETF. ETFMG Alternative Harvest ETF owns 3.77 million shares of the company’s stock, all valued at over $23.65 million. The company bought an additional 8486.0 shares recently to bring their total holdings to about 5.20% of the shares outstanding. Carmignac Portfolio – Long-Short bought 1.68 million shares to see its total holdings expand to 2.09 million shares valued at over $13.1 million and representing 2.88% of the shares outstanding. SPDR S&P Biotech ETF sold 19446.0 shares to bring its total holdings to over 1.94 million shares at a value of $12.16 million. SPDR S&P Biotech ETF now owns shares totaling to 2.68% of the shares outstanding.
Shares of Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP) opened at $8.56, unchanged from a prior closing price of $8.56. However, the script later closed the day at $9.12, up 6.54%. The company’s stock has a 5-day price change of 15.30% and 24.76% over the past three months. CRBP shares are trading 67.03% year to date (YTD), with the 12-month market performance up to 72.73% higher. It has a 12-month low price of $3.29 and touched a high of $8.84 over the same period. Currently, 2.37 million shares have been traded, compared to an average intraday trading volume of 1.74 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 24.19%, 23.04%, and 47.15% respectively.
Institutional ownership of Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP) shares accounts for 57.90% of the company’s 73.89M shares outstanding. Mutual fund holders own 32.73%, while other institutional holders and individual stakeholders account for 36.47% and 13.70% respectively.
It has a market capitalization of $699.50M and a beta (3y monthly) value of 1.47. The earnings-per-share (ttm) stands at -$1.68. Price movements for the stock have been influenced by the stock’s volatility, which stands at 6.75% over the week and 7.59% over the month.
Analysts forecast that Corbus Pharmaceuticals Holdings Inc. (CRBP) will achieve an EPS of -$0.42 for the current quarter, -$0.42 for the next quarter and -$1.73 for 2021. The lowest estimate earnings-per-share for the quarter is -$0.52 while analysts give the company a high EPS estimate of -$0.33. Comparatively, EPS for the current quarter was -$0.32 a year ago. Earnings per share for the fiscal year are expected to decrease by -14.50%, and 2.30% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 6 brokerage firm advisors rate Corbus Pharmaceuticals Holdings Inc. (CRBP) as a “Strong Buy” at a consensus score of 1.60. Specifically, 6 Wall Street analysts polled rate the stock as a buy, while 0 of the 6 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the CRBP, a number of firms have released research notes about the stock. ROTH Capital stated their Buy rating for the stock in a research note on July 07, 2020, with the firm’s price target at $40. BTIG Research coverage for the Corbus Pharmaceuticals Holdings Inc. (CRBP) stock in a research note released on June 17, 2020 offered a Buy rating with a price target of $22. Nomura was of a view on March 26, 2020 that the stock is Buy, while Jefferies gave the stock Buy rating on April 05, 2019, issuing a price target of. Oppenheimer on their part issued Outperform rating on March 20, 2019.